Arix Bioscience PLC (LON:ARIX) should attract more investor interest after its capital market day, according to analysts at Jefferies.

The venture capital company, which invests in disruptive growth companies, reiterated the “buy” recommendation and set the price target at 229p.

“The current 31% discount is cheap in our view and allows no value for Arix’s private assets,” the broker said in a note on Monday.

 Shares were up 1.82% to 112p in afternoon trade.